PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 59 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $390,949 | -27.6% | 37,700 | 0.0% | 0.00% | – |
| Q2 2023 | $539,864 | +177.0% | 37,700 | +38.1% | 0.00% | – |
| Q1 2023 | $194,922 | -22.8% | 27,300 | +21.3% | 0.00% | – |
| Q4 2022 | $252,450 | +44.3% | 22,500 | +42.4% | 0.00% | – |
| Q3 2022 | $175,000 | +42.3% | 15,800 | +8.2% | 0.00% | – |
| Q2 2022 | $123,000 | -22.6% | 14,600 | +24.8% | 0.00% | – |
| Q1 2022 | $159,000 | -37.4% | 11,700 | -9.3% | 0.00% | – |
| Q4 2021 | $254,000 | -28.0% | 12,900 | +17.3% | 0.00% | – |
| Q3 2021 | $353,000 | -15.1% | 11,000 | -10.6% | 0.00% | – |
| Q2 2021 | $416,000 | +5.6% | 12,300 | +17.1% | 0.00% | – |
| Q1 2021 | $394,000 | +4.0% | 10,500 | -7.9% | 0.00% | – |
| Q4 2020 | $379,000 | -14.6% | 11,400 | -5.8% | 0.00% | – |
| Q3 2020 | $444,000 | -3.7% | 12,100 | -13.6% | 0.00% | – |
| Q2 2020 | $461,000 | – | 14,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |